Human Reproduction Update, Vol.2, No.2 pp.153-161, 1996
© European Society of Human Reproduction and Embryology 1996; all rights reserved
Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy
NV Organon, PO Box 20, 5340 BH Oss, Netherlands 0 Corresponding author
Abstract
Single-dose and multiple-rising dose studies of recombinant follicle stimulating hormone (rFSH) in hypogonadotrophic male and female volunteers demonstrated that the rate of FSH absorption after i.m. injection is higher in men than in women. In the absence of endogenous FSH, a correlation between serum FSH and body weight became apparent. The elimination half-life of rFSH was not different between the sexes and was comparable with urinary FSH. However, the in-vitro bio:immuno ratio of serum FSH was significantly higher after the administration of rFSH than after urinary FSH. When rFSH was administered daily with a fixed dose, steady state levels were reached within 3-5 days. Serum FSH concentrations increased in a dose-dependent manner when the daily dose was increased weekly over 3 weeks from 75 to 225 IU. In hypogonadotrophic women, rFSH induced normal follicular growth whereas oestrogen synthesis was impaired. In women pituitary suppressed by a high-dose oral contraceptive, the daily administration of 150 IU rFSH for 1 week induced more and larger antral follicles than the same regimen with urinary FSH, whereas the serum immunoactive FSH concentrations measured 24 h after each dosing were similar. It is concluded that even though equal or lower serum immunoactive FSH concentrations were obtained following the administration of rFSH compared with urinary FSH, circulating bioactivity FSH concentrations were higher. Therefore, the conventional idea that serum immunoreactive FSH correlates positively with the magnitude of the ovarian response should be reconsidered.
Keywords: FSH/pharmacodynamics/pharmacokinetics/Puregon/rFSH
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The Corifollitropin Alfa Dose-finding Study Group A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation Hum. Reprod., August 6, 2008; (2008) den288v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kilani, A. Dakkak, S. Ghunaim, G.E. Cognigni, C. Tabarelli, L. Parmegiani, and M. Filicori A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes Hum. Reprod., June 1, 2003; 18(6): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J.M. Duijkers, C. Klipping, P. J. Boerrigter, C. S.M. Machielsen, J. J. de Bie, and G. Voortman Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females Hum. Reprod., August 1, 2002; 17(8): 1987 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schats, P.D. Sutter, S. Bassil, J.A.M. Kremer, H. Tournaye, J. Donnez, and o. b. o. T. F. a. A. study group Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH Hum. Reprod., August 1, 2000; 15(8): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lenton, A. Soltan, J. Hewitt, A. Thomson, W. Davies, N. Ashraf, V. Sharma, L. Jenner, W. Ledger, and E. McVeigh Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP) Hum. Reprod., May 1, 2000; 15(5): 1021 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.M. Buckler, W.R. Robertson, A. Anderson, M. Vickers, and A. Lambert Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon) Hum. Reprod., December 1, 1999; 14(12): 2969 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Voortman, J. van de Post, R. C. Schoemaker, and J. M.A. van Gerven Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe Hum. Reprod., July 1, 1999; 14(7): 1698 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bergh Recombinant follicle stimulating hormone Hum. Reprod., June 1, 1999; 14(6): 1418 - 1420. [Full Text] [PDF]
|
|
|
|
|
|
F. Raga, F. Bonilla-Musoles, E.M. Casan, and F. Bonilla Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome Hum. Reprod., June 1, 1999; 14(6): 1431 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, S. Lindenberg, A. L. Mikkelsen, T. Eldar-Geva, D. L. Healy, A. Leader, F. J. Rodriguez-Escudero, J. A. Garcia-Velasco, and A. Pellicer A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (PuregonŽ) in women undergoing ovarian stimulation Hum. Reprod., March 1, 1999; 14(3): 622 - 627. [Abstract] [Full Text] [PDF]
|
|